Brief: Actinium Announces Positive Results From Late-Stage Trial For Acute Myeloid Leukemia Therapy
31/10/2022 10:35
Oct 31 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL
PHASE
3 SIERRA TRIAL OF IOMAB-B IN PATIENTS WITH ACTIVE RELAPSED OR
REFRACTORY ACUTE MYELOID LEUKEMIA
* ACTINIUM PHARMACEUTICALS INC - IOMAB-B MET PRIMARY
ENDPOINT
* ACTINIUM PHARMACEUTICALS INC - IOMAB-B WAS ALSO SHOWN TO
BE WELL
TOLERATED GIVEN ITS TARGETED NATURE, CONSISTENT WITH ITS
PREVIOUS CLINICAL DATA
* ACTINIUM PHARMACEUTICALS INC - INTENDS TO PURSUE
ADDITIONAL
INDICATIONS FOR IOMAB-B BEYOND AML
Source text for Eikon: ID:nPn5lP9Lta
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities